A Phase I, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Patients is a PHASE1 clinical asset sponsored by Beijing Boren Hospital in T Cell Lymphoma, T-cell Leukemia. SEO and diligence focus: Efficacy of LCAR-T2C CAR-T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.